Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28961741 | 0.91 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL83067 | 0.91 | KCNH2 (1.00) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5061747 | 0.89 | KCNH2 (0.96) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL23677772 | 0.87 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL28064450 | 0.87 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL2791368 | 0.87 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Bromide SCHEMBL4266727 | 0.85 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL28770065 | 0.85 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL25183370 | 0.85 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Iodide SCHEMBL28601822 | 0.85 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115380021-B | Pharmaceutical composition for preventing or treating diseases associated with muscle weakness comprising alverine, 4-hydroxy alverine, derivatives thereof or pharmaceutically acceptable salts thereof | 安芃蒂公司 | 2025-04-08 | — | — | CN | claimed |
| CN-115380021-A | Pharmaceutical composition for preventing or treating muscle weakness-related diseases comprising alverine, 4-hydroxy alverine, derivatives thereof or pharmaceutically acceptable salts thereof | 安芃蒂公司 | 2022-11-22 | — | — | CN | claimed |
| CN-115380021-B | Pharmaceutical composition for preventing or treating diseases associated with muscle weakness comprising alverine, 4-hydroxy alverine, derivatives thereof or pharmaceutically acceptable salts thereof | 安芃蒂公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20230149326-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AVENTI INC. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230149326-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AVENTI INC. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230149326-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AVENTI INC. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4134363-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Aventi Inc. (KR) | 2023-02-15 | — | — | EP | disclosed |
| CN-115380021-A | Pharmaceutical composition for preventing or treating muscle weakness-related diseases comprising alverine, 4-hydroxy alverine, derivatives thereof or pharmaceutically acceptable salts thereof | 安芃蒂公司 | 2022-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149326-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MTPN, MUSK, MYOF | KCNH2 3774/4885CHRM2 765/4885HTR1A 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.